Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Subscribe To Our Newsletter & Stay Updated